DECADRON ELIXIR 500MCG/5ML ORAL LIQUID

देश: साइप्रस

भाषा: यूनानी

स्रोत: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

सक्रिय संघटक:

DEXAMETHASONE

थमां उपलब्ध:

M S JACOVIDES & CO LTD (0000003082) 8 AYIOS NICOLAOS STR, LEFKOSIA, 1511, 21593

ए.टी.सी कोड:

H02AB02

INN (इंटरनेशनल नाम):

DEXAMETHASONE

डोज़:

500MCG/5ML

फार्मास्यूटिकल फॉर्म:

ORAL LIQUID

रचना:

DEXAMETHASONE (0000050022) 500MCG

प्रशासन का मार्ग:

ORAL USE

प्रिस्क्रिप्शन प्रकार:

Εθνική Διαδικασία

चिकित्सीय क्षेत्र:

DEXAMETHASONE

उत्पाद समीक्षा:

Νομικό καθεστώς: Με Ιατρική Συνταγή; 1 BOTTLE X 100ML (710074001) 100 MILLILITRE - Εγκεκριμένο - Με Ιατρική Συνταγή

उत्पाद विशेषताएं

DECADRON 0.5MG/ML ALGORITHM SAL-LEBANON
ELIXIR
SUMMARY OF PRODUCT CHARACTERISTICS
1.
TRADE NAME OF THE MEDICINAL PRODUCT
DECADRON
®
0.5mg per 5ml Elixir 100ml
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
500mcg / 5ml
For excipients, see 6.1.
3.
PHARMACEUTICAL FORM
Liquid for oral use
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Decadron is indicated as a treatment for certain endocrine and
non-endocrine disorders, in
certain cases of cerebral oedema, and for diagnostic testing of
adrenocortical
hyperfunction.
ENDOCRINE DISORDERS: Primary or secondary adrenocortical
insufficiency, congenital
adrenal hyperplasia.
NON
ENDOCRINE DISORDERS: Dexamethasone may be used in the treatment of non
endocrine corticosteroid responsive conditions, including:
-
Allergy and anaphylaxis: Angioneurotic oedema, anaphylaxis.
-
Arteritis collagenosis: Polymyalgia rheumatica, polyarteritis nodosa.
-
Blood disorders: Haemolytic anaemia, leukaemia, and myeloma.
-
Cardiovascular disorders: Post
myocardial infarction syndrome.
-
Gastro
intestinal: Crohn's disease, ulcerative colitis.
-
Hypercalcaemia: Sarcoidosis.
-
Infections (with appropriate chemotherapy): Miliary tuberculosis.
-
Muscular disorders: Polymyositis.
-
Neurological disorders: Raised intra-cranial pressure secondary to
cerebral
tumours.
-
Ocular disorders: Anterior and posterior uveitis, optic neuritis.
-
Renal disorders: Lupus nephritis.
-
Respiratory disease: Bronchial asthma, aspiration pneumonitis.
-
Rheumatic disorders: Rheumatoid arthritis.
-
Skin disorders: Pemphigus vulgaris.
4.2.
POSOLOGY AND METHOD OF ADMINISTRATION
GENERAL RECOMMENDATIONS FOR ORAL ADMINISTRATION
Dosage requirements are variable and must be individualized according
to the severity of
the disease and the response of the patient. The usual initial dosage
varies from 0.5 mg
to 9 mg a day depending on the disease being treated (for infants and
children, the
recommended doses usually will have to be reduced, but dosage should
be dictated by the
severity of the condition rather than by age or body